The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1510
Celecoxib Safety Revisited
The full article is available to subscribers Subscriber Login   

The results of a clinical trial (PRECISION)1 comparing the cardiovascular safety of the COX-2 selective NSAID celecoxib (Celebrex, and generics) with that of ibuprofen and naproxen, which are nonselective, have been described in the lay press in terms that may overestimate the safety of celecoxib.

NSAID PHARMACOLOGY — NSAIDs inhibit the enzyme cyclooxygenase (COX), which is required for synthesis of prostaglandins and thromboxane. COX-1 inhibition blocks the protective effect of prostaglandins on the gastric mucosa, which can cause gastrointestinal toxicity, and has an antiplatelet effect that can cause bleeding. COX-2 inhibition produces therapeutic anti-inflammatory and analgesic effects, but it has effects on vascular endothelium that can be prothrombotic.

Ibuprofen and naproxen inhibit COX-1 more than COX-2. The COX-2 selective NSAID rofecoxib (Vioxx), ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Celecoxib Safety Revisited
Article code: 1510a
 Electronic, downloadable article - $25